A strategy for O-glycoproteomics of enveloped viruses--the O-glycoproteome of herpes simplex virus type 1

PLoS Pathog. 2015 Apr 1;11(4):e1004784. doi: 10.1371/journal.ppat.1004784. eCollection 2015 Apr.

Abstract

Glycosylation of viral envelope proteins is important for infectivity and interaction with host immunity, however, our current knowledge of the functions of glycosylation is largely limited to N-glycosylation because it is difficult to predict and identify site-specific O-glycosylation. Here, we present a novel proteome-wide discovery strategy for O-glycosylation sites on viral envelope proteins using herpes simplex virus type 1 (HSV-1) as a model. We identified 74 O-linked glycosylation sites on 8 out of the 12 HSV-1 envelope proteins. Two of the identified glycosites found in glycoprotein B were previously implicated in virus attachment to immune cells. We show that HSV-1 infection distorts the secretory pathway and that infected cells accumulate glycoproteins with truncated O-glycans, nonetheless retaining the ability to elongate most of the surface glycans. With the use of precise gene editing, we further demonstrate that elongated O-glycans are essential for HSV-1 in human HaCaT keratinocytes, where HSV-1 produced markedly lower viral titers in HaCaT with abrogated O-glycans compared to the isogenic counterpart with normal O-glycans. The roles of O-linked glycosylation for viral entry, formation, secretion, and immune recognition are poorly understood, and the O-glycoproteomics strategy presented here now opens for unbiased discovery on all enveloped viruses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Flow Cytometry
  • Glycomics
  • Glycoproteins / metabolism
  • Glycosylation
  • Herpesvirus 1, Human / metabolism*
  • Humans
  • Immunohistochemistry
  • Mass Spectrometry / methods*
  • Polymerase Chain Reaction
  • Proteomics / methods*
  • Viral Envelope Proteins / metabolism*

Substances

  • Glycoproteins
  • Viral Envelope Proteins

Grants and funding

This work was in part supported by The Danish Research Councils (1331-00133B), http://ufm.dk/en/research-and-innovation/funding-programmes-for-research-and-innovation/find-danish-funding-programmes (IB, SD, HHW); a programme of excellence 2016 (Copenhagen as the next leader in precise genetic engineering CDO2016: 2016CDO04210) from the University of Copenhagen http://www.cdo.ku.dk/http://research.ku.dk/strengths/excellence-programmes/ (IB, HHW); The Danish National Research Foundation (DNRF107) http://dg.dk/en/ (IB, HHJ, SYV, HHW); Carl Emil Friis og hustru Olga Doris Friis Foundation (HHW); The Lundbeck Foundation http://www.lundbeckfoundation.com/ (HHW), A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til Almene Formaal http://www.apmollerfonde.dk/ (HHW), Kirsten og Freddy Johansen Fonden http://www.kf-j.dk/ (HHW), Mizutani Foundation http://www.mizutanifdn.or.jp/ (SYV) and The Novo Nordisk Foundation http://www.novonordiskfonden.dk/en (HHW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.